Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome
Yusuke YamagaKiyonobu TokuyamaTakehiro KatoRie YamadaMasanori MurayamaTsuneko IkedaNoriyoshi YamakitaTakeshige Kunieda
Author information
JOURNALS OPEN ACCESS

2016 Volume 55 Issue 2 Pages 185-190

Details
Abstract

Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome is a unique clinicopathologic variant of multicentric Castleman's disease that has recently been identified in Japan. Previous reports have shown that affected patients typically respond to immunosuppressive therapy, such as prednisolone and tocilizumab. However, the optimal treatment for refractory TAFRO syndrome, which can be fatal, remains unclear. We herein report a case of tocilizumab-resistant TAFRO syndrome successfully treated with cyclosporin A, indicating that cyclosporine A may be an alternative therapy for refractory TAFRO syndrome.

Information related to the author
© 2016 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top